<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00047229</url>
  </required_header>
  <id_info>
    <org_study_id>PMH-PHL-011</org_study_id>
    <secondary_id>CDR0000257565</secondary_id>
    <secondary_id>NCI-5798</secondary_id>
    <nct_id>NCT00047229</nct_id>
  </id_info>
  <brief_title>Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)</brief_title>
  <official_title>A Phase II Study of G3139 in Combination With Doxorubicin in Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as doxorubicin use different ways to stop tumor
      cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of
      doxorubicin by making tumor cells more sensitive to the drug.

      PURPOSE: Phase II trial to study the effectiveness of combining oblimersen with doxorubicin
      in treating patients who have locally advanced, recurrent, or metastatic hepatocellular
      carcinoma (liver cancer).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the maximum tolerated dose of oblimersen and doxorubicin in patients with
           advanced hepatocellular carcinoma or other incurable solid tumor (closed to accrual as
           of 11/7/03). (Phase I completed as of 1/16/04.)

        -  Determine the efficacy of this regimen, in terms of objective response rate, in these
           patients.

        -  Determine the toxicity of this regimen in these patients.

        -  Determine the time to progression, response duration, progression-free survival, median
           survival, and overall survival rates in patients treated with this regimen.

      OUTLINE: This is a dose-escalation, multicenter study. (Phase I completed as of 1/16/04.)

      Patients receive oblimersen IV continuously on days 1-7 and doxorubicin IV over 5 minutes on
      day 5. Treatment repeats every 4 weeks for up to 10 courses in the absence of disease
      progression or unacceptable toxicity.

      Cohorts of 3-6 patients receive escalating doses of oblimersen and doxorubicin until the
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is
      determined, additional patients*, including 6 patients with hepatocellular carcinoma (HCC),
      are treated at the recommended phase II dose. (Phase I completed as of 1/16/04.)

      NOTE: *Other solid tumors closed to accrual as of 11/7/03; only accruing HCC patients

      PROJECTED ACCRUAL: A total of 12-18 patients will be accrued for the phase I portion of this
      study within 6 months (phase I completed as of 1/16/04). A total of 30 patients will be
      accrued for the phase II portion of this study within 10-15 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of objective response (complete and partial)</measure>
    <time_frame>Up to 280 days</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR. Objective response rate of &gt;= 30% is considered active, and &lt;10% is considered inactive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stable disease rate</measure>
    <time_frame>Up to 280 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 280 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rate</measure>
    <time_frame>Up to 280 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median survival rate</measure>
    <time_frame>Up to 280 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>Up to 280 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Up to 280 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>G3139 in combination with Doxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>oblimersen sodium</intervention_name>
    <arm_group_label>G3139 in combination with Doxorubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>G3139 in combination with Doxorubicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of 1 of the following:

               -  Histologically or cytologically confirmed hepatocellular carcinoma (HCC)

                    -  Locally advanced, recurrent, or metastatic

                    -  Not candidates for surgical/radical therapies

               -  Other solid tumor that is incurable (closed to accrual as of 11/7/03)

          -  At least 1 unidimensionally measurable lesion

               -  At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan

               -  Target lesion may not be in a previously irradiated field unless subsequent
                  progression was documented

          -  No ascites

          -  No known brain metastases

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-2 OR

          -  Karnofsky 60-100%

        Life expectancy

          -  More than 3 months

        Hematopoietic

          -  WBC at least 2,000/mm^3

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic

          -  Bilirubin no greater than 2.0 mg/dL

          -  AST no greater than 5 times upper limit of normal (ULN)

          -  Albumin greater than 3.5 g/dL

          -  No cirrhosis worse than Childs-Pugh class A

        Renal

          -  Creatinine no greater than 1.25 times ULN OR

          -  Creatinine clearance at least 50 mL/min

        Cardiovascular

          -  LVEF normal by MUGA

          -  No symptomatic congestive heart failure

          -  No unstable angina pectoris

          -  No cardiac arrhythmia

        Other

          -  Good nutritional status

          -  No encephalopathy

          -  No other concurrent uncontrolled illness

          -  No ongoing or active infection

          -  No psychiatric illness or social situation that would preclude study participation

          -  No prior allergic reactions to compounds of similar chemical or biological composition
             to oblimersen or doxorubicin

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No more than 1 prior biologic therapy regimen for patients with HCC

          -  At least 4 weeks since prior biologic therapy

        Chemotherapy

          -  Patients with HCC:

               -  No prior systemic chemotherapy

               -  Prior chemotherapy as part of localized chemoembolization therapy may be allowed
                  (no more than 150 mg/m^2 for doxorubicin) if completed at least 8 weeks before
                  study treatment

          -  All other patients (closed to accrual as of 11/7/03):

               -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

               -  No prior doxorubicin, epirubicin, or other anthracycline

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  See Disease Characteristics

          -  At least 4 weeks since prior radiotherapy

          -  No more than 3,000 cGy to fields including substantial bone marrow

        Surgery

          -  At least 8 weeks since prior surgery

          -  Prior liver transplant for HCC allowed

        Other

          -  Recovered from all prior therapy

          -  At least 8 weeks since other locally ablative therapies

          -  No concurrent commercial or other investigational agents or therapies

          -  No other concurrent anticancer therapy

          -  No concurrent combination antiretroviral therapy for HIV-positive patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Knox, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program at London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT00047229</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQÂ® database</description>
  </link>
  <results_reference>
    <citation>Knox JJ, Chen XE, Feld R, Nematollahi M, Cheiken R, Pond G, Zwiebel JA, Gill S, Moore M. A phase I-II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798). Invest New Drugs. 2008 Apr;26(2):193-4. Epub 2007 Dec 4.</citation>
    <PMID>18060598</PMID>
  </results_reference>
  <results_reference>
    <citation>Knox JJ, Chen E, Feld R, et al.: A phase II trial of oblimersen sodium (G3139) in combination with doxorubicin (DOX) in advanced hepatocellular carcinoma (HCC). NCI protocol # 5798. [Abstract] J Clin Oncol 24 (Suppl 18): A-14072, 2006.</citation>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Oblimersen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

